Skip to main content

Diabetes Mellitus: Pharmacotherapy-Sulfonyl Ureas!

 


PHARMACOTHERAPY

Oral and injectable agents are available to treat patients with T2DM who are unable to achieve glycemic control through meal planning and physical activity.

Medications classifications include:

  1.  Sulfonyl Urea's
  2. Nonsylfonylurea Secretagogues (a-Glinides)
  3. Biguanides
  4. Thiazolidinediones
  5. a-Glucosidase Inhibitors
  6. Dipeptidyl Peptidase-4 Inhibitors(Gliptins)
  7. Sodium-glucose co-transporter (SGLT) Inhibitors 
  8. Central-Acting Dopamine Agonists
  9. Bile Acid Sequestrants
  10. Insulin therapy

SULFONYL UREAS

  • Sulfonylureas represent the first class of Oral blood glucose lowering agents approved by the United States.
  • These drugs are classified as either First- or Second-Generation drugs.
  • Both classes of sulfonyl ureas are effective when given at equipotent doses.

Mechanism of Action

  • Sulfonyl ureas enhance insulin secretion by blocking ATP-sensitive potassium channels in the cell membranes of pancreatic beta cells. This action results in membrane depolarization, allowing the influx of calcium to cause the translocation of secretory granules of Insulin to the cell surface and enhances insulin secretion in a non-glucose dependent manner.

Metabolism

  • All sulfonyl ureas undergo hepatic biotransformation with most agents being metabolized by Cytochrome-P450 2C9 Pathway. 
  • The first-generation sulfonyl ureas are most likely to cause drug interaction than the second-generation ones.
  • All sulfonyl ureas except Tolbutamide require dose adjustment or are not recommended for renal impairment.

Clinical Use

  • Sulfonyl ureas blood-glucose lowering agents can be observed in both Fasting and post-prandial levels.

Therapy

  • Monotherapy with these agents generally produce a 1.5-2% decline in A1c levels. and a 60-70mg/dL reduction in Fasting blood glucose levels (FBG).

Adverse Drug Reactions

  • Hypoglycemia
  • Weight Gain
  • Sulfa allergy


**ONLY SULFONYL UREAS THAT DOESNOT REQUIRE DOSE ADJUSTMENTS IS TOLBUTAMIDE**

Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Clinical Presentation and Diagnosis!

 CLINICAL PRESENTATION AND DIAGNOSIS OF DM 2. SCREENING American Diabetes Association (ADA) recommends routine screening for T2 DM every 3 years in all adults starting at 45 years of age. Testing of T2 DM should be considered in any adult, regardless of their age, who have a BMI greater than or equal to 25kg/m2. The ADA does not currently recommend widespread screening for T1 DM because of the relatively low incidence in the general population, although measurement of Islet antibodies may be appropriate for high-risk individuals. 3.GESTATIONAL DIABETES: "Gestational diabetes is the glucose intolerance in women during pregnancy". All pregnant women who have risk factors for T2 DM should be screened for undiagnosed T2 DM at their first prenatal visit using standard diagnostic criteria.  Any women found to have diabetes in the early point at pregnancy is considered to have T2 DM or GDM. All other pregnant women, not currently known to have DM should be screened for GDM with a 75...
Post a Comment
Read more

Hospital Acquired Pneumonia- Definition, Predisposing Factors, Clinical Features and Management!

 HOSPITAL ACQUIRED PNEUMONIA Definition: "HAP refers to a new episode of pneumonia occurring at least 2 days after the administration to hospital. It is the most common Hospital Acquired Infection (HAI) and leading cause of HAI-associated death". Predisposing factors: Aspiration of nasopharyngeal secretion Bacteria introduced into the lower GIT. Bacteriaemia Old age Mode of Spread:  Droplet infection Infecting agent: Bacteria: S.pneumonia , S.aureus , H.influenza Virus: Adenovirus, Corona virus, Herpes Simplex Clinical Features: Purulent sputum New radiological infiltrates Temperature > 38 degree Celsius Leukocytosis Investigations: Chest Pain:  to confirm the diagnosis and exclude complication. Pulse Oximetry : to monitor response to oxygen therapy, if SaO2 < 93% features of sever pneumonia, identify ventilatory failure or acidosis. Cell count:  ESR, Neutrophil leukocytosis Microbiological studies:  for severe CAP and those that do not respond to ...
Post a Comment
Read more

Management of H.pylori and NSAID-associated ulcers Eradication!

MANAGEMENT FOR H.PYLORI ERADICATION It is known that H.pylori infection is associated with over 90% of duodenal ulcers and 80% of Gastric Ulcers. Antibiotics alone or acid-suppressing agents alone, do not eradicate H.pylori . Both therapies act synergistically as growth of the organism occurs at elevated pH and antibiotics efficacy is enhanced during growth. Additionally, increasing intragastric pH may enhance antibiotic absorption. High eradication rates are achieved by a short course of Triple Therapy consisting of:            1 .PPI                                         2. Clarithromycin                         3. Amoxicillin/Metronidazole          in a twice recommended simultaneous regimen. First-Line Therapy :  European Guidelines recommended 1 we...
Post a Comment
Read more